REVVITY, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that REVVITY, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jan 1, 2023 | $741.21M | Mar 1, 2023 |
| FY2022 | Oct 2, 2022 | $711.80M | Mar 1, 2023 |
| FY2022 | Jul 3, 2022 | $895.64M | Mar 1, 2023 |
| FY2022 | Apr 3, 2022 | $963.16M | Mar 1, 2023 |
| FY2022 | Jan 2, 2022 | $1.03B | Mar 1, 2023 |
| FY2022 | Oct 3, 2021 | $861.32M | Mar 1, 2023 |
| FY2022 | Jul 4, 2021 | $910.75M | Mar 1, 2023 |
| FY2022 | Apr 4, 2021 | $1.03B | Mar 1, 2023 |
| FY2020 | Jan 3, 2021 | $1.35B | Mar 2, 2021 |
| FY2020 | Oct 4, 2020 | $964.03M | Mar 2, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $2.86B | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $2.76B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $2.75B | Feb 24, 2026 |
| FY2024 | Jan 1, 2023 | $3.31B | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $3.83B | Feb 27, 2024 |
| FY2022 | Jan 3, 2021 | $2.66B | Mar 1, 2023 |
| FY2021 | Dec 29, 2019 | $2.88B | Mar 3, 2022 |
| FY2020 | Dec 30, 2018 | $2.78B | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $2.26B | Feb 25, 2020 |
| FY2018 | Jan 1, 2017 | $2.12B | Feb 26, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.26B | Feb 27, 2018 |
| FY2016 | Jan 1, 2017 | $2.12B | Feb 28, 2017 |
| FY2015 | Jan 3, 2016 | $2.26B | Mar 1, 2016 |
| FY2014 | Dec 28, 2014 | $2.24B | Feb 24, 2015 |
| FY2014 | Dec 29, 2013 | $2.16B | Feb 24, 2015 |
| FY2014 | Dec 30, 2012 | $2.11B | Feb 24, 2015 |
| FY2011 | Jan 1, 2012 | $1.92B | Feb 28, 2012 |
| FY2010 | Jan 2, 2011 | $1.70B | Mar 1, 2011 |
| FY2010 | Jan 3, 2010 | $1.55B | Mar 1, 2011 |
| FY2010 | Dec 28, 2008 | $1.66B | Mar 1, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jan 1, 2023 | $436.33M | Mar 1, 2023 |
| FY2022 | Oct 2, 2022 | $407.04M | Mar 1, 2023 |
| FY2022 | Jul 3, 2022 | $551.72M | Mar 1, 2023 |
| FY2022 | Apr 3, 2022 | $594.74M | Mar 1, 2023 |
| FY2022 | Jan 2, 2022 | $643.80M | Mar 1, 2023 |
| FY2022 | Oct 3, 2021 | $522.86M | Mar 1, 2023 |
| FY2022 | Jul 4, 2021 | $574.14M | Mar 1, 2023 |
| FY2022 | Apr 4, 2021 | $693.19M | Mar 1, 2023 |
| FY2020 | Jan 3, 2021 | $827.07M | Mar 2, 2021 |
| FY2020 | Oct 4, 2020 | $527.45M | Mar 2, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $241.20M | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $270.39M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $693.09M | Feb 24, 2026 |
| FY2022 | Jan 1, 2023 | $127.66M | Mar 1, 2023 |
| FY2022 | Oct 2, 2022 | $85.35M | Mar 1, 2023 |
| FY2022 | Jul 3, 2022 | $179.21M | Mar 1, 2023 |
| FY2022 | Apr 3, 2022 | $176.96M | Mar 1, 2023 |
| FY2022 | Jan 2, 2022 | $190.18M | Mar 1, 2023 |
| FY2022 | Oct 3, 2021 | $127.74M | Mar 1, 2023 |
| FY2022 | Jul 4, 2021 | $245.93M | Mar 1, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $356.64M | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $346.74M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $300.56M | Feb 24, 2026 |
| FY2022 | Jan 1, 2023 | $137.47M | Mar 1, 2023 |
| FY2022 | Oct 2, 2022 | $110.78M | Mar 1, 2023 |
| FY2022 | Jul 3, 2022 | $232.49M | Mar 1, 2023 |
| FY2022 | Apr 3, 2022 | $261.97M | Mar 1, 2023 |
| FY2022 | Jan 2, 2022 | $299.89M | Mar 1, 2023 |
| FY2022 | Oct 3, 2021 | $195.55M | Mar 1, 2023 |
| FY2022 | Jul 4, 2021 | $308.00M | Mar 1, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $215.84M | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $196.84M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $216.58M | Feb 24, 2026 |
| FY2024 | Jan 1, 2023 | $221.62M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $200.34M | Feb 27, 2024 |
| FY2022 | Jan 3, 2021 | $146.44M | Mar 1, 2023 |
| FY2021 | Dec 29, 2019 | $189.34M | Mar 3, 2022 |
| FY2020 | Dec 30, 2018 | $194.00M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $139.46M | Feb 25, 2020 |
| FY2018 | Jan 1, 2017 | $124.18M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $991.89M | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $994.07M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.02B | Feb 24, 2026 |
| FY2024 | Jan 1, 2023 | $1.03B | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $975.19M | Feb 27, 2024 |
| FY2022 | Jan 3, 2021 | $716.47M | Mar 1, 2023 |
| FY2021 | Dec 29, 2019 | $815.32M | Mar 3, 2022 |
| FY2020 | Dec 30, 2018 | $811.91M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $626.02M | Feb 25, 2020 |
| FY2018 | Jan 1, 2017 | $590.47M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $582.93M | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $628.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $91.27M | Feb 24, 2026 |
| FY2024 | Jan 1, 2023 | $679.81M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $1.41B | Feb 27, 2024 |
| FY2022 | Jan 3, 2021 | $892.18M | Mar 1, 2023 |
| FY2021 | Dec 29, 2019 | $363.47M | Mar 3, 2022 |
| FY2020 | Dec 30, 2018 | $311.04M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $288.45M | Feb 25, 2020 |
| FY2018 | Jan 1, 2017 | $350.62M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $73.52M | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $86.65M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $81.37M | Feb 24, 2026 |
| FY2024 | Jan 1, 2023 | $85.63M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $86.02M | Feb 27, 2024 |
| FY2022 | Jan 3, 2021 | $63.63M | Mar 1, 2023 |
| FY2021 | Dec 29, 2019 | $76.33M | Mar 3, 2022 |
| FY2020 | Dec 30, 2018 | $93.25M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $39.09M | Feb 25, 2020 |
| FY2018 | Jan 1, 2017 | $31.70M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $12.17B | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $12.39B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $13.56B | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | $14.13B | Feb 27, 2024 |
| FY2022 | Jan 2, 2022 | $15.00B | Mar 1, 2023 |
| FY2021 | Jan 3, 2021 | $7.96B | Mar 3, 2022 |
| FY2020 | Dec 29, 2019 | $6.54B | Mar 2, 2021 |
| FY2019 | Dec 30, 2018 | $5.98B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $6.09B | Feb 26, 2019 |
| FY2017 | Jan 1, 2017 | $4.28B | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $4.92B | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $4.73B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $5.69B | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | $6.75B | Feb 27, 2024 |
| FY2022 | Jan 2, 2022 | $7.86B | Mar 1, 2023 |
| FY2021 | Jan 3, 2021 | $4.22B | Mar 3, 2022 |
| FY2020 | Dec 29, 2019 | $3.72B | Mar 2, 2021 |
| FY2019 | Dec 30, 2018 | $3.39B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $3.59B | Feb 26, 2019 |
| FY2017 | Jan 1, 2017 | $2.12B | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $7.25B | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $7.67B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $7.87B | Feb 24, 2026 |
| FY2025 | Jan 1, 2023 | $7.38B | Feb 24, 2026 |
| FY2024 | Jan 2, 2022 | $7.14B | Feb 25, 2025 |
| FY2023 | Jan 3, 2021 | $3.74B | Feb 27, 2024 |
| FY2022 | Dec 29, 2019 | $2.81B | Mar 1, 2023 |
| FY2021 | Dec 30, 2018 | $2.58B | Mar 3, 2022 |
| FY2020 | Dec 31, 2017 | $2.50B | Mar 2, 2021 |
| FY2019 | Jan 1, 2017 | $2.15B | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $6.61B | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $6.46B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $6.53B | Feb 24, 2026 |
| FY2024 | Jan 1, 2023 | $6.48B | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $6.63B | Feb 27, 2024 |
| FY2022 | Jan 3, 2021 | $2.64B | Mar 1, 2023 |
| FY2021 | Dec 29, 2019 | $3.11B | Mar 3, 2022 |
| FY2020 | Dec 30, 2018 | $2.95B | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $3.00B | Feb 25, 2020 |
| FY2018 | Jan 1, 2017 | $2.25B | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $6.05B | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $5.85B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $5.61B | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | $4.95B | Feb 27, 2024 |
| FY2022 | Jan 2, 2022 | $4.42B | Mar 1, 2023 |
| FY2021 | Jan 3, 2021 | $3.51B | Mar 3, 2022 |
| FY2020 | Dec 29, 2019 | $2.81B | Mar 2, 2021 |
| FY2019 | Dec 30, 2018 | $2.60B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $2.38B | Feb 26, 2019 |
| FY2017 | Jan 1, 2017 | $2.12B | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $919.86M | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $1.16B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $913.16M | Feb 24, 2026 |
| FY2024 | Jan 1, 2023 | $454.36M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $603.32M | Feb 27, 2024 |
| FY2022 | Jan 3, 2021 | $387.05M | Mar 1, 2023 |
| FY2021 | Dec 29, 2019 | $191.88M | Mar 3, 2022 |
| FY2020 | Dec 30, 2018 | $163.11M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $202.13M | Feb 25, 2020 |
| FY2018 | Jan 1, 2017 | $359.27M | Feb 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.90B | Feb 27, 2024 |
| FY2022 | Jan 1, 2023 | $4.39B | Mar 1, 2023 |
| FY2021 | Jan 2, 2022 | $4.98B | Mar 3, 2022 |
| FY2020 | Jan 3, 2021 | $1.99B | Mar 2, 2021 |
| FY2019 | Dec 29, 2019 | $2.07B | Feb 25, 2020 |
| FY2018 | Dec 30, 2018 | $1.89B | Feb 26, 2019 |
| FY2017 | Dec 31, 2017 | $2.01B | Feb 27, 2018 |
| FY2016 | Jan 1, 2017 | $1.05B | Feb 28, 2017 |
| FY2015 | Jan 3, 2016 | $1.01B | Mar 1, 2016 |
| FY2014 | Dec 28, 2014 | $1.05B | Feb 24, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 2 | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | 2 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 24, 2026 |
| FY2022 | Jan 1, 2023 | 1 | Mar 1, 2023 |
| FY2022 | Oct 2, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Jul 3, 2022 | 1 | Mar 1, 2023 |
| FY2022 | Apr 3, 2022 | 1 | Mar 1, 2023 |
| FY2022 | Jan 2, 2022 | 1 | Mar 1, 2023 |
| FY2022 | Oct 3, 2021 | 1 | Mar 1, 2023 |
| FY2022 | Jul 4, 2021 | 2 | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 2 | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | 2 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 24, 2026 |
| FY2022 | Jan 1, 2023 | 1 | Mar 1, 2023 |
| FY2022 | Oct 2, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Jul 3, 2022 | 1 | Mar 1, 2023 |
| FY2022 | Apr 3, 2022 | 1 | Mar 1, 2023 |
| FY2022 | Jan 2, 2022 | 1 | Mar 1, 2023 |
| FY2022 | Oct 3, 2021 | 1 | Mar 1, 2023 |
| FY2022 | Jul 4, 2021 | 2 | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 112.28M | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | 120.65M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 123.43M | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | 126.30M | Feb 27, 2024 |
| FY2022 | Jan 2, 2022 | 126.24M | Mar 1, 2023 |
| FY2021 | Jan 3, 2021 | 112.09M | Mar 3, 2022 |
| FY2020 | Dec 29, 2019 | 111.14M | Mar 2, 2021 |
| FY2019 | Dec 30, 2018 | 110.36M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 110.36M | Feb 26, 2019 |
| FY2017 | Jan 1, 2017 | 109.62M | Feb 27, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $32.80M | Feb 24, 2026 |
| FY2025 | Dec 29, 2024 | $34.45M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $34.97M | Feb 24, 2026 |
| FY2024 | Jan 1, 2023 | $35.34M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $32.37M | Feb 27, 2024 |
| FY2022 | Jan 3, 2021 | $31.21M | Mar 1, 2023 |
| FY2021 | Dec 29, 2019 | $31.06M | Mar 3, 2022 |
| FY2020 | Dec 30, 2018 | $31.01M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $30.79M | Feb 25, 2020 |
| FY2018 | Jan 1, 2017 | $30.80M | Feb 26, 2019 |